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Abstract: The urea cycle disorders are caused by deficiency of one of the six hepatic enzymes 
or two transporters involved in detoxification of ammonia. The resulting hyperammonemia 
causes severe brain injury unless aggressive steps are taken to reduce the accumulation of 
ammonia, which is thought to be the most toxic metabolite. This review describes the current 
state of chronic management of urea cycle disorders, focusing on new and emerging therapies. 
Management strategies include the mainstay of treatment, namely dietary protein restriction 
and supplementation with l-arginine or l-citrulline. Several currently approved medications 
utilize and enhance alternative pathways of waste nitrogen excretion (sodium benzoate, sodium 
phenylacetate, sodium phenylbutyrate in several formulations, and glycerol phenylbutyrate), 
working through conjugation of the drug to either glycine (in the case of benzoate) or glutamine, 
the products of which are excreted in the urine. Carglumic acid activates the first committed 
step of conversion of ammonia to urea, carbamoylphosphate synthetase, and thus effectively 
treats defective synthesis of the endogenous activator, N-acetylglutamate, whether due to genetic 
defects or biochemical inhibition of the N-acetylglutamate synthase enzyme. Approaches to neu-
roprotection during episodes of hyperammonemia are discussed, including the use of controlled 
hypothermia (brain cooling), as well as proposed, but as yet untested, pharmacologic therapies. 
Finally, cell-based therapies, including liver transplantation, infusion of fresh or cryopreserved 
hepatocytes, use of stem cells, and new approaches to gene therapy, are reviewed.
Keywords: urea cycle disorders, inherited hyperammonemias, orphan drugs, phenylbutyrate, 
N-carbamyl-l-glutamate
Introduction
Urea cycle disorders (UCDs) are a group of inherited defects of six enzymes and two 
transporters that constitute the urea cycle in the periportal liver cells. Defects in any 
of the enzymes or transporters lead to the respective disorders including arginase 1 
deficiency, argininosuccinate lyase (ASL) deficiency, argininosuccinate synthetase 
deficiency, citrullinemia type 2 (caused by the defect of the citrin transporter), 
carbamoylphosphate synthetase 1 (CPS1) deficiency, N-acetylglutamate synthase 
(NAGS) deficiency, ornithine transcarbamylase (OTC) deficiency, and hyperorni-
thinemia-hyperammonemia-homocitrullinuria syndrome (caused by the defect of 
mitochondrial ornithine transporter) (Figure 1). The main function of the urea cycle 
is the detoxification of ammonia and the synthesis of arginine. Defects of any of the 
urea cycle enzymes in the liver can result in metabolic decompensation characterized 
by hyperammonemia, which is life threatening if the treatment is started late or if the 
diagnosis is missed.1
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Figure 1 enzymes and transporters of the urea cycle.
Notes: The urea cycle is shown as it is present in mitochondrion and cytosol. The encircled plus sign indicates stimulation of CPS1 by NAG. Adapted from Häberle J, 
Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32. © 2012 Häberle et al.; licensee 
BioMed Central Ltd. Available from http://www.ojrd.com/content/7/1/32#.11
Abbreviations: ARG1, arginase 1; ASL, argininosuccinate lyase; ASS, argininosuccinate synthetase; citrin, mitochondrial aspartate–glutamate antiporter; CPS1, 
carbamoylphosphate synthetase 1; GDH, glutamate dehydrogenase; GLNase, glutaminase; NAG, N-acetylglutamate; NAGS, N-acetylglutamate synthase; OTC, ornithine 
transcarbamylase; ORNT1, mitochondrial ornithine transporter.
UCDs are panethnic with variable prevalence in different 
populations and an overall incidence of about 1 in 35,000.2 
Initial presentation of a UCD can be at any age but about 
half of the patients present shortly after birth, triggered by 
postnatal catabolism.3 Other common triggering factors, 
characterized by endogenous protein catabolism, include 
viral infections and fasting. Patients with onset of symp-
toms outside the newborn period are classified as late-onset 
UCDs.4–6
The most neurotoxic compound metabolites appear to be 
ammonia itself, which is responsible for most of the clini-
cal symptoms and complications. The exact mechanisms of 
ammonia neurotoxicity are not completely understood. Dif-
ferent effects of accumulating ammonia on the brain include 
swelling of astrocytes via glutamine accumulation, energy 
deficit through mitochondrial dysfunction, enhanced oxida-
tive stress due to increased nitric oxide (NO) production, 
increased extracellular glutamate stimulating N-methyl-d-
aspartate (NMDA) receptors, inhibition of the tricarboxylic 
acid cycle, and secondary creatine deficiency.7–9
The main goal of treatment is to avoid hyperam-
monemia in order to prevent neurological sequelae. 
Scrupulous avoidance of acute and chronic hyperammonemia 
may be associated with better prognosis for patients with 
UCDs.10 On the other hand, the prognosis with respect to 
survival is commonly considered as poor in cases where 
the ammonia concentration in blood is .1,000 µmol/L 
(reference ,100 in newborns and ,50 outside the 
neonatal period) or with duration of hyperammonemic 
coma .24 hours.11 Infants who do survive typically have 
severe and permanent brain injury, thus many specialists 
recommend against aggressive intensive care when treatment 
is delayed from the time of initial presentation.
The mainstay of chronic treatment is reduction of 
dietary protein to the minimum required to support normal 
endogenous protein synthesis and normal growth, along 
with supplementation of essential amino acids, vitamins, 
and trace elements. Other common treatment strategies 
include the nitrogen scavenging drugs, such as sodium 
phenylbutyrate (NaPB), licensed in 1996 for oral/enteral 
use by the United States Food and Drug Administration 
(FDA) as Buphenyl® in the US, (Hyperion Therapeutics, 
Brisbane, CA, USA), and Ammonaps® in Europe (Swedish 
Orphan  Biovitrum Ltd, Stockholm, Sweden), the new drug 
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formulation  glycerol  phenylbutyrate (GPB; FDA-approved 
as RAVICTI®  [Hyperion Therapeutics, Brisbane, CA, USA]), 
sodium phenylacetic acid (NaPA), and sodium benzoate 
(SBZ; the combination of phenylacetic acid (PAA) and SBZ 
is available as an FDA-approved drug for intravenous appli-
cation, AMMONUL® [Ucyclyd Pharma, Inc., Scottsdale, 
AZ, USA]), and the urea cycle intermediates l-citrulline 
(for oral/enteral use only) and l-arginine (for oral/enteral 
or iv use), the latter being available as free base or hydro-
chloride solution.11–13 Use of either or both of the latter two 
compounds, available as chemical compounds only, depends 
on the specific disorder and aims for excretion of citrulline 
(containing one waste nitrogen atom) or argininosuccinic acid 
(containing two waste nitrogen atoms) in the urine.
In spite of these dietary and pharmacological treatment 
measures, considerable risk of hyperammonemic decom-
pensation remains, especially in the severe UCDs. Thus, 
liver transplantation, which is currently considered the only 
curative treatment, is often recommended early in the course 
of the disease in case of neonatal-onset UCDs or an unstable 
course in any patient with UCDs.11,14,15 Liver transplanta-
tion replaces the complete urea cycle, which is only fully 
expressed in liver, but other cell types that express individual 
component enzymes, particularly argininosuccinic acid lyase, 
are not corrected.
There is certainly a need for novel therapies, both for the 
treatment of acute hyperammonemia and for the long-term 
management of UCDs, since the present therapeutic situation 
is far from ideal. A better understanding of the pathology in 
ammonia (neuro) toxicity has opened the path for a variety 
of novel therapeutic approaches, although most have not yet 
added to the armamentarium of UCD drugs. First, we will 
describe the few recent products approved for the treatment 
of UCDs. Second, we will discuss novel therapeutic strategies 
that provide hope for an improved prognosis for individuals 
with UCDs in the future.
Novel drugs already brought  
to the market
Glycerol phenylbutyrate (RAviCTi®)
The basis to alternative pathway therapy was recognized 
100 years ago with the demonstration that SBZ could divert 
urea nitrogen to hippurate.16 Shortly thereafter, a similar 
observation noted that PAA, when given orally, resulted in 
urinary excretion of phenylacetylglutamine.17 PB, which is 
converted to PAA in the liver, is now used more frequently 
for enteral therapy, because it has low odor and is better tol-
erated by patients. Since its introduction to the treatment of 
UCDs,18 the use of endogenous pathways for waste nitrogen 
excretion has become a mainstay of management of patients 
with UCD.19
Recently, a new formulation of PB was brought to the 
market. The new drug, GPB, FDA-approved as RAVICTI®, 
is a pre-prodrug containing three molecules of PB 
joined to glycerol in ester linkage to form a triglyceride. 
The pre-prodrug, GPB, is hydrolyzed in the small intestine 
by pancreatic lipases and releases PB and glycerol. The prod-
rug, PB, is metabolized in the liver to the active compound 
PAA. Given the required GPB hydrolysis, gastrointestinal 
 absorption of PB is slower than with NaPB.
When compared with NaPB in a Phase II study in eleven 
pediatric patients above age 6 years (mean, 10.2 years), GPB 
was shown to be at least equivalent to NaPB with respect 
to ammonia control.20 In that crossover study, performed 
when the blood ammonia was clinically well controlled at 
baseline, switchover from NaPB to a PB-equimolar GPB dose 
was well tolerated and resulted in about 25% lower average 
ammonia exposure (assessed as ammonia 24-hour area under 
the curve [AUC]). Mean blood ammonia  concentrations 
were mainly ,60 µmol/L in the GPB as well as in the 
NaPB-treated patients, and glutamine levels did not change 
significantly after switching to GPB.
In a Phase III double-blinded, randomized crossover 
study in 44 adult patients performed consecutively, treatment 
with GPB was non-inferior to NaPB if ammonia control was 
likewise assessed as 24-hour AUC.21 When the results of the 
latter study were pooled together with data from two similarly 
designed short-term comparisons of GPB versus NaPB (one 
in pediatric patients),20 ammonia 24-hour AUC and plasma 
glutamine were significantly lower with GPB,21 findings that 
are recently confirmed by other studies in pediatric patients 
with UCD.22,23 As a preliminary finding from one study,21 
executive function in the study population seemed to have 
improved, although this observation, made after only one year 
of treatment, must be confirmed in future studies.
In addition to different pharmacokinetics, the main 
advantage of GPB from the patients’ point of view may be 
the much improved palatability of GPB. The drug comes as 
an essentially tasteless liquid. Despite its oily consistency, 
patients have little difficulty swallowing the drug. In pediatric 
patients, this may result in better compliance and lessening of 
the burden of disease. Other potential benefits include mark-
edly reduced volumes of drug to be consumed; one teaspoon 
of GPB liquid provides an equimolar dose to approximately 
13 large tablets of NaPB. The sodium salt of PB also appears 
to cause significant gastric discomfort, which is absent in the 
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triglyceride (GPB), where the acidic PB is released in the 
small intestine and more slowly. Finally, the sodium load in 
therapeutic doses of NaPB is measured in gram quantities, 
which may contribute to multiple unpleasant effects on fluid 
balance and blood pressure.
Phenylbutyrate (Pheburane®)
Another formulation of NaPB was introduced to the European 
market in 2013 (licensed by the European Medicines Agency 
[EMA] as Pheburane®; Lucane Pharma, Paris, France). The 
drug consists of small spherical sugar cores, contributing to 
a sugar content of ∼50% of the weight of the drug, which are 
coated sequentially in two separate layers with sodium PBA 
and ethylcellulose, the latter being a taste-masking agent for 
active substances.24 Pheburane®, formulated as tasteless and 
odor-free granules, is recommended for oral use only and 
should not be administered by a nasogastric or gastrostomy 
tube because of its slow dissolution. Importantly, the sodium 
content of this formulation, 5.4 mmol sodium for each gram 
of NaPB, is identical to the other NaPB formulations avail-
able in the market.
Pharmacodynamic and pharmacokinetic properties are 
the same as in the active compound, PB, resulting likewise 
in conversion to PAA and subsequent conjugation with glu-
tamine to form phenylacetylglutamine, which is then excreted 
in the urine.24 Accordingly, the new formulation reduces the 
unpleasant taste, which should lead to improved compli-
ance and eventually result in better efficacy of long-term 
treatment and better outcomes, especially in the pediatric 
patient population.25
N-Carbamyl-l-glutamate (Carbaglu®)
N-Carbamyl-l-glutamate (carglumic acid; Carbaglu; Orphan 
Europe Recordati Group, Paris, France) is a licensed drug 
(both by the FDA and by the EMA) for the treatment of the 
rare NAGS deficiency.26–28 This defect leads to deficiency 
of N-acetylglutamate (NAG), the allosteric activator of the 
first urea cycle enzyme, CPS1. Carglumic acid is a chemical 
analogue of NAG and has been demonstrated to efficiently 
enter the mitochondrion. Thus, treatment with carglumic 
acid effectively substitutes for the NAG deficiency, although 
the pharmaceutical agent is not regulated by consumption of 
a protein containing meal in the same way as endogenous 
NAG. Nevertheless, NAGS deficiency is the only UCD for 
which an easy and highly efficacious remedy is available, 
which allows the patients to lead a normal life, with no need 
for low-protein diet or other drugs except during the periods 
of illness.11,29,30
In addition, carglumic acid has been licensed in Europe 
for the treatment of acute hyperammonemia in three of 
the organic acidurias (methylmalonic aciduria; propionic 
acidemia; and isovaleric acidemia), which are inherited 
disorders of branched-chain amino acid degradation.28,31 In 
these conditions, hyperammonemia results from inhibition of 
NAGS during states of metabolic decompensation, presum-
ably due to accumulation of specific inhibitory compounds 
such as methylcitrate or propionyl-CoA.
A further application of carglumic acid, the use in 
patients with CPS1 deficiency and potentially also in 
patients with OTC deficiency, has recently been suggested 
and is currently the subject of a multicenter Phase II study 
in the US. The rationale for this use is based on the assump-
tion that additional activation of a mutant CPS1, thereby 
maximizing the flux through the urea cycle, may improve 
the overall ammonia detoxification capacity. This may be the 
case, in particular, if mutations affect the allosteric domain 
of the CPS1 protein, which comprises the C-terminal part 
of the protein. This theoretical concept has been supported 
by a number of (mainly single) patient studies in which a 
beneficial effect was shown.32 More recently, isotope studies 
performed in a small number of CPS1-deficient patients pro-
vide evidence for the efficacy of carglumic acid treatment, 
demonstrating increased flux through the urea cycle.33 This 
is further supported by studies in insect cell-derived purified 
recombinant CPS1, in which carglumic acid exhibited an 
activity increasing effect in some of the mutants.34 Notably, 
this effect was not only limited to mutations within the 
C-terminal part of CPS1 but also found in single missense 
changes far distant in the secondary structure of CPS1.
Likewise, for males with partial OTC deficiency, ie, with 
residual enzyme activity, or in female carriers of OTC muta-
tions with hepatic mosaicism due to random X-inactivation, 
pharmacological upregulation of CPS1 enzyme activity may 
lead to increased flux through the OTC-deficient enzyme, or 
in cells expressing the normal enzyme in female carriers.
Drugs with a potential  
for development
NO supplementation
The recent elucidation of a cytosolic multienzyme com-
plex including argininosuccinate synthetase, ASL, and NO 
synthase,35,36 and evidence of NO deficiency suggested by 
reduced nitrosylation of marker compounds in patients with 
ASL deficiency, suggest an explanation for some of the 
hitherto poorly understood clinical findings in ASL-deficient 
patients, namely, arterial hypertension, chronic liver 
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disease, and ammonia-independent neurodevelopmental 
deterioration.37 Importantly, impaired NO-mediated 
relaxation of the vasculature has been restored both in 
ASL-deficient mice and in a single ASL-deficient human 
with treatment refractory arterial hypertension by NO 
 supplementation.38 Thus, the role of NO supplementation 
for the subgroup of patients affected by ASL deficiency will 
need to be determined in clinical trials.
NMDA receptor blockade and other 
neuroprotective agents
Since ammonia neurotoxicity is in part mediated 
through activation of the NMDA receptors by glutamate, 
targeting this receptor by pharmacological blockade is 
an obvious therapeutic strategy; however, there are no 
research activities reported that specif ically address 
UCDs. Thus, the reader is referred to literature on other 
disorders.39
A number of other therapeutic targets have been inferred 
from research into ammonia neurotoxicity, as reviewed by 
Braissant et al,8 unfortunately, none of them have yet been 
evaluated in clinical trials. Nevertheless, they are listed in 
Table 1 to illustrate the large variety of potential therapeu-
tic targets that may, at least in part, come into clinics in 
the future. Other nitrogen scavenger substances, such as 
l-ornithine-phenylacetate or l-ornithine-l-aspartate, have 
also been proposed, although possible advantages over 
currently existing treatments are not clear.
Other therapeutic strategies
UCDs cannot be cured by drugs alone. It is clear that addi-
tional or alternative strategies are needed. Currently, liver 
transplantation by restoring the defective enzyme in the 
liver is the only correction for the ineffective urea cycle; 
thus, it can be reasonably recommended for all severe 
UCDs, unless there are already neurological sequelae from 
previous episodes of hyperammonemic decompensation 
rendering the extent of preservation of cognitive functions 
small or irrelevant.11,15,40 Even then, liver transplant may be 
considered to ease the burden of care and enhance the quality 
of life for affected individuals, mainly by normalizing the 
diet and removing the need for expensive scavenger medica-
tions and nutritional supplements, and for their families by 
reducing the anxiety of the constant risk of rapid metabolic 
decompensation. It is also possible that liver transplantation 
may be less expensive over the course of a lifetime than the 
current standard medical care. It should be remembered that 
liver transplant does not replace those component enzymes 
of the urea cycle that are expressed in non-hepatic tissues, 
especially argininosuccinic acid lyase, which is involved in 
NO synthesis. In addition, the life-long need for immunosup-
pression must be considered.
Because cadaveric liver transplantation is not immediately 
available for most patients and is technically challenging in 
newborns and small infants, several bridging therapies are cur-
rently being considered or already evaluated in clinical trials.
Hepatocyte transplantation
As a less-invasive but potentially effective approach, trans-
plantation of (fresh or cryopreserved) human hepatocytes 
was suggested in the 1990s.41 Most researchers regard this 
as a potential bridging therapy for newborns with severe 
initial hyperammonemic decompensation at significant risk 
of further ammonia neurotoxicity if recurrent crises were 
to occur.42–44 This is a particularly attractive alternative for 
newborns in whom full organ transplantation carries high 
risks. Another advantage is increased availability of cells, as 
the cryopreserved cells can be stored until needed. It should 
be noted that, as in liver transplantation, there is a need for 
immunosuppression.
Concerns have been raised about the viability of cryo-
preserved hepatocytes, not only because these cells may 
be derived from organ donors not suitable for full organ 
transplantation because of long ischemia times, but also 
because of concerns toward mitochondrial damage due to 
cryopreservation.45 The latter concern could be overcome by 
the use of freshly isolated cells that may have better viability.46 
Table 1 Potential neuroprotective agents
Agent Proposed mechanism of action
NOS inhibitors To mitigate the ammonia-induced upregulation 
of NO54
Creatine To treat cerebral creatine deficiency caused 
by low arginine levels as found in all enzymatic 
defects of the urea cycle (except AR1 
deficiency), to treat ammonia-induced cerebral 
energy deficits, and to protect axonal growth55–57
Acetyl-l-carnitine To treat ammonia-induced cerebral energy 
deficits58
inhibition of  
CDK5/p25
To protect neurons from ammonia-induced 
death59
CNTF To protect oligodendrocytes from ammonia 
neurotoxicity60
MAPK inhibitors To inhibit the ammonia-induced activation of the 
MAPK pathway60,61
GS inhibitors inhibition of brain GS will reduce glutamine 
accumulation in astrocytes, hereby limiting 
osmotic cerebral edema62,63
Abbreviations: CDK, cyclin-dependent kinase; CNTF, ciliary neurotrophic factor; 
GS, glutamine synthetase; MAPK, mitogen-activated protein kinase; NOS, nitric 
oxide synthase.
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At least two clinical trials are currently underway to address 
this approach to therapy. An ongoing multicenter, open-
label clinical trial using historical controls in the US and 
Europe evaluating safety and efficacy of cryopreserved 
hepatocyte transplantation is in progress (Clinicaltrials.
gov identifier NCT01195753). An additional, single-center 
study using freshly isolated hepatocytes transplanted into an 
irradiated liver to enhance engraftment and expansion of the 
grafted cells is also in progress (Clinicaltrials.gov identifier 
NCT01345578).
Stem cell transplantation
Another alternative approach, in principle with the same 
rationale as the aforementioned hepatocyte transplantation 
approach, is the proposed transfusion of stem cells.47–49 These 
cells may exhibit advantages over mature hepatocytes in 
terms of efficacy and may have the additional benefit of being 
able to be produced in large quantities in vitro.49
Gene therapy
Gene therapy is a research focus for several inherited meta-
bolic diseases including UCDs. In fact, in the most com-
mon UCD, OTC deficiency, a dose-escalating study was 
performed as early as in 1999. Unfortunately, this trial was 
stopped due to overwhelming, and ultimately fatal, viral 
sepsis from the vector in one of the subjects,50 which put the 
entire field at hold for many years. Recent advances in vector 
biology and development have brought gene therapy back 
to the list of possible future therapies for UCDs,51 although 
the suitability of adenoviral-associated vectors for treatment 
of newborns remains the subject of debate. A recent review 
article on this topic describes the current status of, and pros-
pects for, gene therapy for UCD treatment.52
Therapeutic hypothermia
Since damage to the brain during hyperammonemia is the 
most relevant complication in UCDs, neuroprotective mea-
sures are warranted. Among these, therapeutic hypothermia 
has been proposed as potentially beneficial as it has been 
observed in other conditions, including traumatic brain injury 
or hypoxic–ischemic encephalopathy.
A recent pilot study in six newborns with UCDs, and 
one case with isovaleric acidemia, a classical organic 
acidemia, all affected by severe hyperammonemia, has 
proven the feasibility of adjunct therapeutic hypothermia.53 
Currently, a randomized multicenter study is being planned 
in US and European centers. This study is designed to 
ascertain whether treatment with hypothermia during the 
initial  hyperammonemic decompensation can improve the 
long-term neurological outcome of patients presenting with 
hyperammonemic crisis.
Summary
Treatment of UCDs is still very challenging and there were 
only few new developments in pharmacological therapy in 
recent years. An improvement not only of palatability but 
probably also of pharmacological properties is the new for-
mulation of glycerol phenylbutyrate that acts as an alternative 
pathway of waste nitrogen excretion. Carglumic acid, able to 
activate CPS1 as the first committed step of ammonia conver-
sion to urea, can be useful for genetic defects or biochemical 
inhibition of the NAGS enzyme. Other therapeutic strate-
gies that are not yet available but subject of studies include 
approaches to neuroprotection (eg, the use of controlled hypo-
thermia aiming for brain cooling), cell-based therapies (eg, 
infusion of fresh or cryopreserved hepatocytes, use of stem 
cells), and new approaches to gene therapy. Overall, novel 
pharmacological developments for treating patients with 
UCDs are much desired as the currently available treatment 
options are still far from being optimal. As all UCDs have 
low incidences, such novel therapies will require the joint 
interest and enthusiasm of scientists and industry dedicated 
to the field of rare diseases.
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